Tilray Brands, Inc. (TLRY) stock
TLRYNasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends May 31
Financials through Q1 FY2027, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 8, 2026Score 11/3087% below fair value
$2.25−0.10 (-4.26%)
Close on Nov 18, 2026Market cap $332.52MP/E –Yield –
Tilray Brands operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Tilray Brands's operating income for the twelve months ending Aug 31, 2026 was -$89.17M. For fiscal 2026 it was -$63.03M. The highest annual figure on record is -$7.05M in fiscal 2016.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | May 31, 2026 | -$63.03M | – |
| FY2025 | May 31, 2025 | -$2.28B | – |
| FY2024 | May 31, 2024 | -$174.75M | – |
| FY2023 | May 31, 2023 | -$1.37B | – |
| FY2022 | May 31, 2022 | -$610.40M | – |
| FY2019 | Dec 31, 2019 | -$304.14M | – |
| FY2018 | Dec 31, 2018 | -$57.84M | – |
| FY2017 | Dec 31, 2017 | -$7.50M | – |
| FY2016 | Dec 31, 2016 | -$7.05M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ3 2026 | Aug 31, 2026 | -$24.05M | -1249.8% |
| Q4 FY2026CQ2 2026 | May 31, 2026 | -$16.45M | – |
| Q3 FY2026CQ1 2026 | Feb 28, 2026 | -$26.39M | – |
| Q2 FY2026CQ4 2025 | Nov 30, 2025 | -$22.28M | – |
| Q1 FY2026CQ3 2025 | Aug 31, 2025 | $2.09M | – |
| Q4 FY2025CQ2 2025 | May 31, 2025 | -$1.44B | – |
| Q3 FY2025CQ1 2025 | Feb 28, 2025 | -$759.93M | – |
| Q2 FY2025CQ4 2024 | Nov 30, 2024 | -$42.22M | – |
| Q1 FY2025CQ3 2024 | Aug 31, 2024 | -$36.57M | – |
| Q4 FY2024CQ2 2024 | May 31, 2024 | -$16.53M | – |
| Q3 FY2024CQ1 2024 | Feb 29, 2024 | -$82.10M | – |
| Q2 FY2024CQ4 2023 | Nov 30, 2023 | -$41.76M | – |
| Q1 FY2024CQ3 2023 | Aug 31, 2023 | -$34.36M | – |
| Q4 FY2023CQ2 2023 | May 31, 2023 | -$89.98M | – |
| Q3 FY2023CQ1 2023 | Feb 28, 2023 | -$1.21B | – |
| Q2 FY2023CQ4 2022 | Nov 30, 2022 | -$51.79M | – |
| Q1 FY2023CQ3 2022 | Aug 31, 2022 | -$21.18M | – |
| Q4 FY2022CQ2 2022 | May 31, 2022 | -$467.42M | – |
| Q3 FY2022CQ1 2022 | Feb 28, 2022 | -$18.08M | – |
| Q2 FY2022CQ4 2021 | Nov 30, 2021 | -$55.53M | – |
| Q1 FY2022CQ3 2021 | Aug 31, 2021 | -$69.37M | – |
| Q4 FY2019CQ4 2019 | Dec 31, 2019 | -$216.62M | – |
| Q3 FY2019CQ3 2019 | Sep 30, 2019 | -$23.79M | – |
| Q2 FY2019CQ2 2019 | Jun 30, 2019 | -$32.96M | – |
| Q1 FY2019CQ1 2019 | Mar 31, 2019 | -$28.44M | – |
| Q4 FY2018CQ4 2018 | Dec 31, 2018 | -$22.91M | – |
| Q3 FY2018CQ3 2018 | Sep 30, 2018 | -$20.01M | – |
| Q2 FY2018CQ2 2018 | Jun 30, 2018 | -$10.99M | – |
| Q1 FY2018CQ1 2018 | Mar 31, 2018 | -$3.74M | – |
| Q4 FY2017CQ4 2017 | Dec 31, 2017 | -$2.61M | – |
| Q3 FY2017CQ3 2017 | Sep 30, 2017 | -$2.18M | – |
| Q2 FY2017CQ2 2017 | Jun 30, 2017 | -$2.32M | – |
| Q1 FY2017CQ1 2017 | Mar 31, 2017 | -$388.00K | – |
See a number that looks wrong?